Dexcom (DXCM) EPS (Weighted Average and Diluted) (2013 - 2026)

Dexcom (DXCM) has 14 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.51 in Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.51, up 88.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.33 (up 73.88% YoY), and the FY2025 annual result was $2.09, up 47.18% from the prior year.
• EPS (Weighted Average and Diluted) declined to $0.51 in Q1 2026 per DXCM's latest filing, from $0.67 in the prior quarter.
• Over five years, EPS (Weighted Average and Diluted) peaked at $0.7 in Q3 2025 and troughed at $0.12 in Q2 2022.
• A 5-year average of $0.36 and a median of $0.34 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
• On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 2300.0% in 2022 and fell as far as 58.93% in 2022.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.22 in 2022, then surged by 177.27% to $0.61 in 2023, then plunged by 37.7% to $0.38 in 2024, then jumped by 76.32% to $0.67 in 2025, then retreated by 23.88% to $0.51 in 2026.
• Business Quant data shows DXCM's EPS (Weighted Average and Diluted) at $0.51 in Q1 2026, $0.67 in Q4 2025, and $0.7 in Q3 2025.